0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Special Feature |

Image of the Month—Diagnosis FREE

[+] Author Affiliations

Section Editor: Carl E. Bredenberg, MD

More Author Information
Arch Surg. 2010;145(2):208. doi:10.1001/archsurg.2009.140-b.
Text Size: A A A
Published online

An incisional biopsy was performed and, on final pathologic review of the specimen, the patient was found to have infiltrating ductal carcinoma consistent with the inflammatory type. The tumor was strongly estrogen receptor/progesterone receptor–positive and HER2/neu–negative. Metastatic workup revealed multiple distant metastases to the brain, liver, and adrenal glands. Chemotherapy and adjuvant hormonal therapy were started.

Inflammatory breast cancer is a rare but aggressive subtype of breast cancer, which historically was considered to be uniformly fatal. Treatment with local therapy, surgery, radiation therapy, or both surgery and therapy results in few long-term survivors. Inflammatory breast cancer accounts for approximately 5% of all cases of breast cancer.1 In general, women with inflammatory breast cancer present at a younger age, are more likely to have metastatic disease at diagnosis, and have shorter survival times than women with noninflammatory breast cancer. According to the latest revision of the American Joint Committee on Cancer staging guidelines, inflammatory carcinoma is classified as T4d, which means that all patients with inflammatory carcinoma have stage IIIB, IIIC, or IV disease, depending on the nodal status and presence of distant metastases.2

Inflammatory breast carcinoma is not associated with a particular histologic subtype and can occur in association with infiltrating ductal or lobular, small cell, medullary, and large cell carcinomas. The characteristic pathologic finding is dermal lymphatic invasion by carcinoma, which can lead to obstruction of the lymphatic drainage, causing the clinical picture of erythema and edema. However, the diagnosis of inflammatory carcinoma is made based on clinical findings, and the absence of dermal lymphatic invasion does not exclude the diagnosis.3 Patients with the clinical features of inflammatory carcinoma should be treated aggressively even if they do not have pathologic evidence of dermal lymphatic invasion. In many centers, surgery is used as part of a combined modality approach to the treatment of inflammatory breast cancer. Nevertheless, its value is controversial given the high risk of metastatic relapse and poor overall prognosis.4,5

Return to Quiz Case.

Submissions

The Editor welcomes contributions to the Image of the Month. Manuscripts should be submitted via our online manuscript submission and review system (http://manuscripts.archsurg.com). Articles and photographs accepted will bear the contributor's name. Manuscript criteria and information are per the Instructions for Authors for Archives of Surgery (http://archsurg.ama-assn.org/misc/ifora.dtl). No abstract is needed, and the manuscript should be no more than 3 typewritten pages. There should be a brief introduction, 1 multiple-choice question with 4 possible answers, and the main text. No more than 2 photographs should be submitted. There is no charge for reproduction and printing of color illustrations.

Correspondence: Alexey Markelov, MD, Department of Surgery, Easton Hospital, 250 S 21st St, Easton, PA 18045 (Dr.markelov@gmail.com).

Accepted for Publication: March 31, 2009.

Author Contributions:Study concept and design: Markelov and Kohli. Acquisition of data: Markelov and Kohli. Analysis and interpretation of data: Markelov and Kohli. Drafting of the manuscript: Markelov and Kohli. Critical revision of the manuscript for important intellectual content: Markelov and Kohli. Statistical analysis: Markelov and Kohli. Administrative, technical, and material support: Markelov and Kohli. Study supervision: Markelov and Kohli.

Financial Disclosure: None reported.

Levine  PHSteinhorn  SCRies  LGAron  JL Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst 1985;74 (2) 291- 297
PubMed
Singletary  SEAllred  CAshley  P  et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20 (17) 3628- 3636
PubMed Link to Article
Hance  KWAnderson  WFDevesa  SSYoung  HALevine  PH Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 2005;97 (13) 966- 975
PubMed Link to Article
De Boer  RHAllum  WHEbbs  SR  et al.  Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol 2000;11 (9) 1147- 1153
PubMed Link to Article
Smoot  RLKoch  CADegnim  AC  et al.  Single-center experience with inflammatory breast cancer, 1985-2003. Arch Surg 2006;141 (6) 567- 573
PubMed Link to Article

Figures

Tables

References

Levine  PHSteinhorn  SCRies  LGAron  JL Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst 1985;74 (2) 291- 297
PubMed
Singletary  SEAllred  CAshley  P  et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002;20 (17) 3628- 3636
PubMed Link to Article
Hance  KWAnderson  WFDevesa  SSYoung  HALevine  PH Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst 2005;97 (13) 966- 975
PubMed Link to Article
De Boer  RHAllum  WHEbbs  SR  et al.  Multimodality therapy in inflammatory breast cancer: is there a place for surgery? Ann Oncol 2000;11 (9) 1147- 1153
PubMed Link to Article
Smoot  RLKoch  CADegnim  AC  et al.  Single-center experience with inflammatory breast cancer, 1985-2003. Arch Surg 2006;141 (6) 567- 573
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles